

HEMOSENSE INC  
Form S-8  
July 26, 2005

As filed with the Securities and Exchange Commission on July 26, 2005

Registration No. 333-\_\_\_\_\_

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM S-8

### REGISTRATION STATEMENT

*Under*

*The Securities Act of 1933*

---

## HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**77-0452938**  
(I.R.S. Employer  
Identification Number)

**651 River Oaks Parkway**

**San Jose, California 95134**

**(408) 719-1393**

(Address including zip code, and telephone number, including area code, of principal executive offices)

---

**1997 STOCK PLAN**

**2005 EQUITY INCENTIVE PLAN**

(Full title of the plans)

---

**James D. Merselis**

**President and Chief Executive Officer**

**HemoSense, Inc.**

**651 River Oaks Parkway**

**San Jose, California 95134**

**(408) 719-1393**

(Name, address, and telephone number, including area code, of agent for service)

---

*Copy to:*

**Michael J. Danaher**

**David J. Saul**

**David B. Crawford**

**Wilson Sonsini Goodrich & Rosati**

**Professional Corporation**

**650 Page Mill Road**

**Palo Alto, CA 94304-1050**

**(650) 493-9300**

---

**CALCULATION OF REGISTRATION FEE**

---

<b>Title of Securities to be Registered</b>	<b>Maximum Amount to be</b>	<b>Proposed Maximum Offering Price</b>	<b>Proposed Maximum Aggregate</b>	<b>Amount of Registration Fee</b>
---------------------------------------------	-------------------------------------	------------------------------------------------	-------------------------------------------	---------------------------------------

Edgar Filing: HEMOSENSE INC - Form S-8

	<b>Registered</b>	<b>Per Share</b>	<b>Offering Price</b>	
Common Stock \$0.001 par value	992,656 shares (1)	\$0.99(2)	\$983,174.80(3)	\$115.72
Common Stock \$0.001 par value	92,206 shares (4)	\$6.38(5)	\$588,274.28	\$69.24
<b>TOTAL</b>	<b>1,084,862 shares</b>		<b>\$1,571,449.08</b>	<b>\$184.96</b>

- 
- (1) For the sole purpose of calculating the registration fee, the number of shares to be registered under this Registration Statement has been broken down into two subtotals. This subtotal represents the sum of shares issuable upon exercise of presently outstanding options (options that have been granted as of the date of this Registration Statement) issued under the 1997 Stock Plan.
  - (2) Computed in accordance with Rule 457(h) under the Securities Act of 1933, as amended, solely for the purpose of calculating the total registration fee. Computation based on the weighted average exercise price (rounded to the nearest cent) at which the options outstanding whose exercise will result in the issuance of the shares being registered may be exercised.
  - (3) Calculated in accordance with Rule 457(h) based on the aggregate exercise price for all presently outstanding options described in note 1 above.
  - (4) This subtotal represents the sum of shares issuable upon exercise of options that are available for grant under the 1997 Stock Plan as of the date of this Registration Statement and shares to be granted under the 2005 Equity Incentive Plan.
  - (5) Estimated in accordance with Rule 457(h) solely for the purpose of calculating the total registration fee. Computation based upon the average of the high and low sales prices of the common stock (rounded to the nearest cent) as reported on the American Stock Exchange on July 19, 2005.
-

**HEMOSENSE, INC.**

**REGISTRATION STATEMENT ON FORM S-8**

**PART II**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

We incorporate by reference in this Registration Statement the following documents and information filed by HemoSense, Inc. with the Securities and Exchange Commission:

- (1) Our prospectus filed on June 29, 2005 pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the Securities Act ).
- (2) Our description of the common stock shares contained in our Registration Statement on Form 8-A filed pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act ), and as declared effective on June 28, 2005.

All documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

An investment partnership comprised of current and former members of and persons associated with Wilson Sonsini Goodrich & Rosati, P.C., as well as one current member of Wilson Sonsini Goodrich & Rosati, P.C. own interests representing less than 0.2% of our outstanding common stock.

**Item 6. Indemnification of Directors and Officers.**

Section 145(a) of the Delaware General Corporation Law provides in relevant part that [a] corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful. With respect to derivative actions, Section 145(b) of the Delaware General Corporation Law provides in relevant part that [a] corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor . . . [by reason of such person's

service in one of the capacities specified in the preceding sentence] against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

As permitted by Section 145 of the Delaware General Corporation Law, our Amended and Restated Certificate of Incorporation includes a provision that eliminates the personal liability of our directors and officers for monetary damages for breach of their fiduciary duty as a director or officer to the fullest extent permitted under Delaware General Corporation Law. In addition, our Bylaws provide that we shall indemnify our directors and officers and may indemnify our employees and other agents to the extent permitted under Delaware General Corporation Law. As permitted by our Bylaws, we have obtained insurance on behalf of our directors and officers against any liability arising out of his or her actions in such capacity, regardless of whether we have the power to indemnify such individual against such liability under the provisions of the Delaware General Corporation Law.

We have entered into, and intend to enter into in the future, indemnification agreements with each of our directors and executive officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law, as well as certain additional procedural protections.

The Amended and Restated Investors' Rights Agreement dated February 7, 2005, as amended (the "Rights Agreement"), between us and certain investors provides for indemnification of our directors and officers in connection with registration of our common stock under the Rights Agreement.

The indemnification provision in our Amended and Restated Certificate of Incorporation, Bylaws and Rights Agreement and the indemnification agreements entered into between us and our directors and executive officers, may be sufficiently broad to permit indemnification of our officers and directors for liabilities arising under the Securities Act.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

<u>Exhibit</u> <u>Number</u>	<u>Description</u>
5.1	Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.
10.2*	1997 Stock Plan.
10.3*	2005 Equity Incentive Plan.

## Edgar Filing: HEMOSENSE INC - Form S-8

- 23.1 Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
- 23.2 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (see Exhibit 5.1).
- 24.1 Power of Attorney (see page II-4).

---

\* Incorporated by reference to exhibits filed with our Registration Statement on Form S-1 (file no. 333-123705), and as declared effective on June 28, 2005.

**Item 9. Undertakings.**

A. We hereby undertake:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

B. We hereby undertake that, for purposes of determining any liability under the Securities Act, each filing of our annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to applicable law, our Amended and Restated Certificate of Incorporation, Bylaws, Rights Agreement or indemnification agreements, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, HemoSense, Inc., a corporation organized and existing under the laws of the State of Delaware, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Jose, State of California, on this 26 day of July, 2005.

HEMOSENSE, INC.

By: /s/ JAMES D. MERSELIS

---

James D. Merselis  
 President and Chief Executive Officer  
 (Principal Executive Officer)

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints James D. Merselis and Paul Balsara, jointly and severally, as his attorneys-in-fact, with full power of substitution in each, for him in any and all capacities to sign any amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
/s/ JAMES D. MERSELIS <hr/> James D. Merselis	President, Chief Executive Officer and Director  (Principal Executive Officer)	July 26, 2005
/s/ PAUL BALSARA <hr/> Paul Balsara	Vice President, Finance and Chief Financial  Officer (Principal Financial and Accounting Officer)	July 26, 2005
/s/ GREGORY M. AYERS, M.D., Ph.D. <hr/> Gregory M. Ayers, M.D., Ph.D.	Director	July 26, 2005
/s/ EDWARD F. BRENNAN, Ph.D. <hr/> Edward F. Brennan, Ph.D.	Director	July 26, 2005

Edgar Filing: HEMOSENSE INC - Form S-8

/s/ ROBERT D. ULRICH, Ph.D.

---

Director

July 26, 2005

Robert D. Ulrich, Ph.D.

/s/ KURT C. WHEELER

---

Director

July 26, 2005

Kurt C. Wheeler

II-4

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
5.1	Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation.
10.2*	1997 Stock Plan.
10.3*	2005 Equity Incentive Plan.
23.1	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
23.2	Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation  (see Exhibit 5.1).
24.1	Power of Attorney (see page II-4).

---

\* Incorporated by reference to exhibits filed with our Registration Statement on Form S-1 (file no. 333-123705), and as declared effective on June 28, 2005.

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**EXHIBITS**

Registration Statement on Form S-8

**HEMOSENSE, INC.**

July 26, 2005